Ausgabe 4/2020
Inhalt (30 Artikel)
Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21
Chandra Bose Prabaharan, Allan Boyao Yang, Divya Chidambaram, Karthic Rajamanickam, Scott Napper, Meena Kishore Sakharkar
Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer
Dongying Liu, Haiyang Zhang, Shaohua Ge, Dan Lin, Jiayi Han, Guoguang Ying, Yi Ba
Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells
Arusha Modi, Meenakshi Singh, Gopichand Gutti, Ozasvi R. Shanker, Vinay Kumar Singh, Sunita Singh, Sushil Kumar Singh, Satyajit Pradhan, Gopeshwar Narayan
Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
Maximilian Hochmair, Barbara Rath, Lukas Klameth, Ernst Ulsperger, Christoph Weinlinger, Andreas Fazekas, Adelina Plangger, Robert Zeillinger, Gerhard Hamilton
The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma
Xi’an Li, Guangdong Hou, Zheng Zhu, Fei Yan, Fuli Wang, Di Wei, Yu Zheng, Jiarui Yuan, Wanxiang Zheng, Geng Zhang, Ping Meng, Yan Guo, Xia Li, Libo Yao, Lan Shen, Jianlin Yuan
Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells
Katrin Manda, Tina Präkelt, Tonja Schröder, Stephan Kriesen, Guido Hildebrandt
A new series of acetohydroxamates shows in vitro and in vivo anticancer activity against melanoma
Gabriela C. Segat, Camila G. Moreira, Evelyn C. Santos, Melina Heller, Raquel C. Schwanke, Alexander V. Aksenov, Nicolai A. Aksenov, Dmitrii A. Aksenov, Alexander Kornienko, Rodrigo Marcon, João B. Calixto
Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines
Agnieszka Wróbel, Beata Kolesińska, Justyna Frączyk, Zbigniew J. Kamiński, Anna Tankiewicz-Kwedlo, Justyna Hermanowicz, Robert Czarnomysy, Dawid Maliszewski, Danuta Drozdowska
Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3
Jingjie Sun, Yuping Du, Xinxin Zhang, Zhuoya Wang, Yuxi Lin, Qiaoling Song, Xiao Wang, Jihui Guo, Shanshan Li, Jing Nan, Jinbo Yang
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells
Toshimi Hoshiko, Yasushi Kubota, Takuya Akisawa, Tatsuro Watanabe, Kazuaki Tanigawara, Junichi Yano, Shinya Kimura
7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells
Mariana S. Sonego, Natália V. Segatto, Lucas Damé, Mariana Fronza, Carolina B. Gomes, Thais Larré Oliveira, Fabiana Kömmling Seixas, Lucielli Savegnago, Kyle M. Schachtschneider, Diego Alves, Tiago Collares
Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts
Jingya Han, Yan Zhao, Xinming Zhao, Tuo Ma, Tiancheng Hao, Jiahui Liu, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang
Matteucinol, isolated from Miconia chamissois, induces apoptosis in human glioblastoma lines via the intrinsic pathway and inhibits angiogenesis and tumor growth in vivo
Ana Gabriela Silva, Viviane Aline O. Silva, Renato J. S. Oliveira, Allisson Rodrigues de Rezende, Rafael César Russo Chagas, Lúcia Pinheiro Santos Pimenta, Wanderson Romão, Hélio Batista Santos, Ralph Gruppi Thomé, Rui Manuel Reis, Rosy Iara Maciel de Azambuja Ribeiro
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Shunji Takahashi, Motohide Uemura, Tomokazu Kimura, Yoshihide Kawasaki, Atsushi Takamoto, Akito Yamaguchi, Amal Melhem-Bertrandt, Elaina M. Gartner, Takashi Inoue, Rio Akazawa, Takeshi Kadokura, Toshiki Tanikawa
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
Markus Joerger, Anastasios Stathis, Yannis Metaxas, Dagmar Hess, Mara Mantiero, Michael Mark, Matthias Volden, Thomas Kaindl, Marc Engelhardt, Patrice Larger, Heidi Lane, Peter Hafner, Nicole Levy, Silvia Stuedeli, Cristiana Sessa, Roger von Moos
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer
Rachel Goodwin, Derek Jonker, Eric Chen, Hagen Kennecke, Michael Cabanero, Ming-Sound Tsao, Michael Vickers, Caryn Bohemier, Howard Lim, Heather Ritter, Dongsheng Tu, Lesley Seymour
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer
Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Abadi Gebretensae, Alwin D. R. Huitema, Marloes G. van Dongen, Jos H. Beijnen, Aram Oganesian
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)
Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Johann S. de Bono, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Jacques De Grève, Jan H. M. Schellens
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma
Anthony Wood, Saby George, Nabil Adra, Sreenivasulu Chintala, Nur Damayanti, Roberto Pili
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Johann S. de Bono, Jan H. M. Schellens
Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial
Wanqi Zhu, Hui Mei, Li Jia, Hanxi Zhao, Xiaolin Li, Xiangjiao Meng, Xianguang Zhao, Ligang Xing, Jinming Yu
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
Sarah Lapointe, Warren Mason, Mary MacNeil, Craig Harlos, Roger Tsang, Joana Sederias, H. Artee Luchman, Samuel Weiss, John P. Rossiter, Dongsheng Tu, Lesley Seymour, Martin Smoragiewicz
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
Johanna C. Bendell, Helge G. Bischoff, Jimmy Hwang, Hans Christian Reinhardt, Thomas Zander, Xuejing Wang, Scott Hynes, Celine Pitou, Robert Campbell, Philip Iversen, Daphne L. Farrington, Katherine Bell-McGuinn, Michael Thomas
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
Albiruni R. Abdul Razak, Wilson H. Miller Jr, Geoffrey L. Uy, Steven Blotner, Anne-Marie Young, Brian Higgins, Lin-Chi Chen, Lia Gore
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population
Goldy C. George, Tito R. Mendoza, Eucharia C. Iwuanyanwu, Meryna Manandhar, Solmaz F. Afshar, Sarina A. Piha-Paul, Apostolia Tsimberidou, Aung Naing, Charles S. Cleeland, David S. Hong
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
Toshihiko Doi, Nobuaki Matsubara, Akira Kawai, Norifumi Naka, Shunji Takahashi, Hiroji Uemura, Noboru Yamamoto
Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients
Linlin Zhang, Liang Chen, Hao Yu
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report
Atsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, Kei Irie, Shoji Fukushima, Keisuke Tomii
Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor
Anne Ségolène Cottereau, Léopoldine Bricaire, Jennifer Arrondeau, Amina Dechmi, Françoise Montravers, Romain Coriat, Jerome Clerc, Lionel Groussin, Florence Tenenbaum
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
Yosuke Ando, Takahiro Hayashi, Reiko Sugimoto, Seira Nishibe, Kaori Ito, Kenji Kawada, Yoshiaki Ikeda, Shigeki Yamada, Kazuyoshi Imaizumi